FDA Moves to Keep IV ‘Starter Nutrition’ Flowing to Fragile Newborns

The FDA has moved to prevent a shortage of neonatal starter parenteral nutrition — the intravenous nutrition given to premature and critically ill newborns who cannot yet be fed by mouth or feeding tube — after two compounding facilities announced they were permanently closing.

On September 4, 2026, the agency issued immediately-in-effect guidance titled Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates.

What starter PN is and why hours matter

Parenteral nutrition delivers amino acids, dextrose, electrolytes, minerals and other nutrients directly into the bloodstream, bypassing a digestive system that is either immature or not functioning.

“Starter” PN is the standardised formulation given in the first hours of life, before a bespoke prescription tailored to an individual infant’s laboratory values can be compounded. Because it is standardised, it can be prepared in advance and held ready — which is the entire point. A very premature infant has almost no nutritional reserve, and delay in establishing nutrition and glucose supply carries real consequences for growth and neurodevelopment.

“Starter parenteral nutrition is especially important for premature newborns” who require nutrition soon after birth, said Michael Davis, M.D., Ph.D., acting director of the FDA’s Center for Drug Evaluation and Research.

What triggered the action

Children’s hospitals raised concerns about continued access after two outsourcing facilities discontinued certain standardised neonatal starter PN products as part of permanently shutting down. The FDA’s announcement does not name them.

Notably, the agency acted before a shortage materialised — responding to a foreseeable gap rather than to empty shelves.

Why two closures can threaten national supply

This is the part that explains the urgency, and it turns on an unusual corner of US drug regulation.

Neonatal starter PN is generally not a mass-produced, FDA-approved commercial drug product. It is compounded — prepared by mixing sterile components — largely by 503B outsourcing facilities, a category created after the 2012 fungal meningitis outbreak traced to contaminated compounded injections. Those facilities register with the FDA, follow manufacturing quality standards, and may produce sterile products in bulk without patient-specific prescriptions.

It is a small sector. Sterile compounding at scale is technically demanding, heavily scrutinised, and low-margin, and few facilities specialise in neonatal formulations, where the volumes are tiny and the tolerance for error is nil. When a supply base is that concentrated, the loss of two participants is not an incremental reduction — it can remove most of the available capacity.

What the FDA actually did

The guidance sets out temporary regulatory and enforcement priorities under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A covers state-licensed pharmacies and federal facilities; 503B covers outsourcing facilities.

In practical terms, this is the FDA signalling that it will exercise enforcement discretion to let a wider set of compounders make these products than would ordinarily be permitted — expanding who can legally fill the gap without waiting for new approvals. It took effect immediately on publication rather than going through the usual comment period, which is the mechanism the agency reserves for situations where delay itself is the hazard.

“The FDA is committed to deploying every regulatory tool available to prevent critical supply chain gaps from threatening patient care,” said acting Commissioner Kyle Diamantas, J.D.

The trade-off being made

Enforcement discretion in sterile compounding is not a cost-free decision, and it is worth being explicit about why.

The 503B category exists because compounded sterile injectables killed people when oversight was inadequate. Broadening who may prepare an intravenous product for the most vulnerable possible patients trades one risk against another: the certain harm of newborns going without nutrition versus the possible harm of a wider, less specialised production base. The FDA has judged the first to be the greater danger, and the policies are explicitly temporary — but the tension is real rather than rhetorical.

This has happened before

Intravenous nutrition and fluid supply has proved fragile more than once. When Hurricane Maria struck Puerto Rico in 2017, damage to manufacturing there triggered a national shortage of intravenous saline bags that disrupted hospital care across the United States for months — a demonstration of how much of a critical product line can depend on a small number of physical sites.

Individual parenteral nutrition components have also gone into shortage repeatedly, forcing clinicians to ration amino acids, lipids or trace elements and to make substitutions in feeds for patients who have no oral alternative. Neonatal intensive care units are the least equipped setting in which to improvise, because dosing is weight-based, margins for error are minimal, and the patients cannot wait.

The structural problem this points to

Shortages concentrate where products are essential, complex to make and commercially unattractive. Neonatal starter PN hits all three: a small patient population, a demanding sterile process, and no pricing power. The market provides little incentive to build redundancy, so supply resides with a handful of facilities and remains one business decision away from disruption.

Regulatory flexibility can bridge a gap. It does not create manufacturing capacity, and it does not change the economics that made the capacity fragile. Regulatory news, not medical advice.